Sorafenib [SOR2]
The treatment of differentiated thyroid cancer after radioactive iodine where the following criteria are met:
- This application is made by and the first cycle of systemic anti-cancer therapy with sorafenib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy
- This patient has a confirmed histological diagnosis of differentiated thyroid carcinoma (papillary or follicular or Hurtle cell type) 3.The patient has either metastatic disease or inoperable locally advanced disease
- The disease is refractory to radioactive iodine
- The disease is progressive and is either symptomatic or imminently likely to become symptomatic
- The patient is treatment naïve to both lenvatinib and sorafenib unless the patient has had to discontinue lenvatinib within 3 months of starting lenvatinib because of toxicity (ie there is lenvatinib toxicity which cannot be managed by dose delay or dose modification) and there has been no disease progression whilst on lenvatinib. Note: Sequential use of sorafenib and then lenvatinib is only funded if the patient has to discontinue sorafenib because of intolerance within 3 months of its start and if the disease has not progressed whilst the patient is on sorafenib. The use of sorafenib after disease progression on or after lenvatinib is not funded and vice versa.
- The patient has an ECOG performance status of 0 or 1 or 2.
- Sorafenib is to be continued as long as clinical benefit is observed or until there is unacceptable toxicity or patient choice to stop treatment.
- A formal medical review as to whether treatment with sorafenib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment
- No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)
- Sorafenib is to be otherwise used as set out in its Summary of Product Characteristics
NHS funded From: 06 November 2018
Additional information
Current Form Version
Note
The data on this page was produced using version 1.361 of the CDF list, downloaded from an archive of NHS England’s website on 08 May 2025 at 22:10.
If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.